New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 18, 2012
19:11 EDTMNOVMedicNova extends MN-166 patent position in Europe
MediciNova announced that it has received Notices of Allowance from the European Patent Office, EPO, for two pending patent applications. One covers the use of ibudilast, MN-166, in drug addiction and the other provides for ibudilast use to enhance opioid analgesia in acute pain settings. MN-166 is the company's lead drug development candidate for certain neurological conditions, including progressive multiple sclerosis, drug addiction, and pain.
News For MNOV From The Last 14 Days
Check below for free stories on MNOV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
19:03 EDTMNOVMedicNova to initiate clinical trial of MN-166 in ALS
Subscribe for More Information
August 18, 2014
19:04 EDTMNOVMedicNova announces positive interim results of MN-166 phase 2a study
MediciNova announced positive interim results of a phase 2a clinical trial of MN-166 in opioid dependence. The study is being conducted at Columbia University and the New York State Psychiatric Institute and led by Dr. Sandra Comer, Professor of Neurobiology. The interim analysis was performed after the first seven patients had completed the study, which required a 6-week stay on the inpatient unit. MN-166 demonstrated a number of beneficial effects on the subjective, analgesic, and reinforcing effects of oxycodone. MN-166 significantly decreased the craving for heroin, cocaine, and tobacco. MN-166 also decreased the positive subjective effects of oxycodone measured by mean responses to statements such as "I Feel High" and "I Liked the Dose." MN-166 also enhanced the analgesic effects of oxycodone. MN-166 reduced the sum score on the McGill Pain Questionnaire, reduced the mean rating on the Painful scale, and reduced the mean rating on the Bothersome scale. Finally, MN-166 decreased the reinforcing effects of oxycodone.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use